The prognosis for older patients with acute myeloid leukemia (AML) is poor, with overall survival (OS) rates of approximately 10% at 4-5 years, and high morbidity owing to adverse therapeutic outcomes. Therefore, identification of effective, yet less toxic, therapies is essential and could be elucidated through the application of pharmacogenetics to treatment trials. Although clinical outcomes in adult AML patients may be partially explained by recognized prognostic markers, including age, cytogenetics and de novo versus secondary disease, it is possible that inherited polymorphisms in enzymes that activate or detoxify chemotherapeutic agents, as well as those that protect from reactive oxygen species (ROS) generated by therapy, may account for some of the variability in toxicity and efficacy of treatment.
Anthracycline antibiotics, such as daunorubicin, are used in the treatment of leukemia, and are known to generate high levels of ROS, including hydrogen peroxide and hydroxyl radicals, 1 which are highly destructive to cells. Glutathione S-transferases (GSTs), which are active in detoxification of organic epoxides, hydroperoxides and unsaturated aldehydes, including reactive purine and pyrimidine bases and lipid peroxidases produced by reactive oxidant damage to DNA and lipids, respectively, 2 are induced under conditions of oxidative stress. Variability in GSTs owing to genetic polymorphisms resulting in reduced activity of GSTA1 and total gene deletions of GSTM1 and GSTT1 could thereby alter protection of both tumor and normal cells from ROS, and impact treatment outcomes.
We evaluated the effects of genetic polymorphisms in GSTM1, GSTT1 and GSTA1 on response to treatment and relapse-free survival (RFS) and OS as well as on adverse outcomes resulting from therapy, in the context of two clinical trials for adult AML. Data and samples were from patients (n ¼ 200) diagnosed with AML by French-American-British (FAB) criteria (456 years) enrolled in two separate Southwest Oncology Group (SWOG) clinical trials (SWOG-9031, SWOG-9333). SWOG-9031 was a randomized, double-blind, placebocontrolled trial conducted from 1992-1994 of daunomycin (45 mg/m 2 /day Â 3) and ara-C (200 mg/m 2 /day Â 7) with or without recombinant human granulocyte colony-stimulating factor (rhG-CSF). In SWOG-9333 (1995 SWOG-9333 ( -1998 , patients were randomized to the remission induction chemotherapy regimen of SWOG-9031 without rhG-CSF or to mitoxantrone (10 mg/m 2 / day Â 5) and etoposide (100 mg/m 2 /day Â 5). Because the results of SWOG-9333 indicated that survival was poorer with mitoxantrone/etoposide, the present study included patients from the ara-C/daunorubicin arm only. Patients were primarily Caucasian (85%) and ranged in age from 56 to 88 years (mean and median ¼ 68 years), with approximately equal proportions of men and women. Patients with AML secondary to myelodysplastic syndrome (MDS) or prior chemotherapy were included in both trials. Because the eligibility criteria, treatment regimens and outcomes were similar for those patients receiving ara-C and daunomycin in both trials, we combined data from the two trials for these analyses.
Mononuclear cells were separated from the bone marrow or peripheral blood (if fewer than three vials of bone marrow remained in the SWOG Myeloid Repository) collected from AML patients before initiation of chemotherapy, using Ficolldensity centrifugation. JR Weiss et al. (unpublished data) demonstrated a high concordance rate between genotype calls for 80 matched bone marrow and buccal cell samples from patients with AML, demonstrating the feasibility of using bone marrow samples as a source of genomic DNA. DNA was then extracted using Gentra PureGene DNA extraction kits (Gentra, Minneapolis, MN, USA), according to the manufacturer's instructions. Genotyping was conducted by BioServe Biotechnologies (Laurel, MD, USA). For GSTM1 and GSTT1, a multiplex polymerase chain reaction technique that detects homozygous deletions was used, including primers for the b-globin gene as an internal control. Genotypes for GSTA1 (rs No. 3957357) were determined using Sequenom's high-throughput matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, as previously described by Ambrosone et al.
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Controls for genotype and two non-template controls were included on each plate, as well as 10% duplicate samples.
Analyses included the assessment of patient and disease characteristics by GST genotype, using w 2 analysis, Fisher's exact test, analysis of variance and Kruskal-Wallis or Wilcoxon's rank sum tests as appropriate. Distributions of OS and RFS were compared between genotypes using log-rank tests. Proportional hazards regression analysis was performed to evaluate differences of OS and RFS between genotypes after adjusting for patient characteristics with prognostic significance. OS was measured from the date of randomization until death from any cause, with observation censored on the date the patient was last known to be alive. RFS was measured from the date complete remission (CR) was achieved until the first relapse of AML or death from any cause, with observation censored on the date of last contact for patients without report of relapse. Standard methods for binary data, such as w 2 tests and logistic regression models, were used to examine treatment response and toxicity outcomes. Organ groups were created by combining categories defined by SWOG toxicity criteria for SWOG-9031 and the NCI Common Toxicity Criteria (version 2.0) for SWOG-9333. Toxicities of induction chemotherapy were combined into the following organ groups: genitourinary, gastrointestinal, liver, lung, metabolic and cardiovascular. For each GST gene and each organ group, logistic regression analyses were run to test whether the distributions of highest toxicity grade varied among genotypes (excluding patients with toxicity(ies) of unknown grade). In effect, this compares the cumulative distribution of toxicity grade among genotypes.
None of the patient or disease characteristics, including age, race, sex, secondary versus de novo leukemia, cytogenetic group (favorable, intermediate or unfavorable), 4 FAB classification, % marrow blasts, white blood cells (WBCs) or peripheral blasts, varied significantly by genotypes for any of the GST genes. Of the 200 patients, 86 (43%) achieved a CR and 65 (33%) had resistant disease (RD). The remaining 49 patients died before marrow recovery or adequate assessment of response. Fifteen patients were last known to be alive between 22 months and 10.9 years after entering their respective studies (median ¼ 6.3 years); the other 185 (93%) are now deceased. There were no statistically significant differences in OS by any GST genotypes (log-rank P-value 0.54 for heterogeneity among three GSTA1 genotypes, 0.60 and 0.64 for differences between GSTM1 and GSTT1 genotypes, respectively), and adjustment for other covariates such as age, race, gender, cytogenetic risk group, previous cancer, FAB, WBC count, blast percentage and AML onset did not appreciably alter the hazard ratio (HR) estimates in Cox regression analysis (Table 1) . Similarly, no GST genotype was associated with RFS or CR (data not shown). Risk of RD was somewhat lower in patients with the GSTM1 null genotype (28%) compared to those with the GSTM1 present genotype (40%), (odds ratio (OR) ¼ 0.52, 95% confidence interval (CI) ¼ 0.27-1.00). A complementary, although nonsignificant, difference was observed in CR rates (39% for M1 present, 49% for null) (OR ¼ 1.62, 95% CI ¼ 0.87-3.07). No significant differences were observed for GSTT1 or GSTA1. There was also no effect of combined 'at-risk' alleles for GSTM1, GSTT1 and GSTA1 (data not shown). Early mortality, that is, deaths within 30 or 60 days after entering the clinical trial, was also examined, and results did not vary significantly for GST genotypes (data not shown). Relationships between GST genotypes and toxicity of induction chemotherapy were evaluated in 197 patients (toxicity data were not available for three patients). No GST genotype was significantly associated with toxicity in any organ group (Table 2) . However, among patients with the low activity GSTA1 n B alleles, there was a suggestive trend for increased risk of higher grade cardiovascular toxicity (GSTA1 n A/ n B: OR ¼ 1.56, 95% CI ¼ 0.52-5.78; GSTA1 n B/ n B: OR¼ 2.25, 95% CI ¼ 0.75-8.31), although associations were not statistically significant.
Because GSTs are involved in detoxification of both carcinogens and chemotherapeutic agents, we analyzed the distribution of GST genotypes with respect to the onset of AML (secondary versus de novo). Forty-three (23%) of the 200 patients had AML that was secondary to prior MDS or leukemogenic exposure. No differences were observed comparing de novo and secondary AML by GSTT1 and GSTA1 genotypes. However, for GSTM1, we observed a marginally significant difference. Among patients with GSTM1 genotype data, 29% of those with GSTM1 present had secondary AML, compared to 16% of those with GSTM1 null alleles (P ¼ 0.029).
In our study, we found no statistically significant associations between GST genotypes and treatment outcomes in AML patients, despite the fact that the GSTs play an important role in the detoxification of reactive intermediates resulting from a diverse range of cytotoxic drugs, including alkylating agents and anthracycline antibiotics, and also neutralize ROS. These results differ from those of previous studies examining GST genotypes and treatment outcomes in AML patients. Autrup et al. Abbreviations: AML, acute myeloid leukemia; CI, confidence interval; GI, gastrointestinal; GST, glutathione S-transferase; GU, genitourinary; OR, odds ratio. N, number of patients evaluated for toxicities of induction chemotherapy; Events, number of patients with toxicity of known grade (number with toxicity but unknown grade shown in parentheses). a Present or common genotype served as reference group for all regression analysis.
Letters to the Editor examined 89 patients with AML and noted that patients with GSTM1 null genotypes had a trend toward a poorer survival than those patients with present alleles, with no effects of GSTT1 and GSTP1 genotypes. In a study of 106 adults with AML, GST null genotypes were associated with shorter OS (HR ¼ 2.4, 95% CI ¼ 1.2-4.9). 6 Another study with 193 patients 7 found that GSTT1 null genotypes were associated with poorer OS. Rates of early death after the initiation of chemotherapy were also higher in the GSTT1 null group than the GSTT1 present group, with no effects for GSTM1 genotype. Similarly, Davies et al. 8 observed in a population of 306 children with AML or MDS that those patients with the GSTT1 null genotype had reduced survival compared to those with at least one GSTT1 present allele (52 versus 40% at 5 years). Patients with GSTM1 null genotypes had similar survival to those possessing at least one GSTM1 allele.
These conflicting results may be attributable to chance, owing to the small sample sizes in several of the previous studies. Dosage and type of chemotherapy regimen may also play a role in the discrepant results, with two previous studies noting associations only among those patients receiving low-dose therapy with variant alleles. 5, 8 All of the patients in our study were treated according to the same chemotherapy regimen with ara-C and daunorubicin at standard doses. Thus, if an effect is only seen in those patients receiving a low dose of chemotherapy, this could explain the lack of associations observed in our data. The increased age of the study population could also affect the results in our study compared to the previous studies. It is possible that the extremely poor survival in older adult patients with AML precludes any more subtle effects that may result from differences in metabolism of chemotherapeutic agents or response to ROS. The contribution of minor differences in protection from reactive metabolites by GST genotypes may not be sufficient to overcome the exceedingly poor prognosis of adults with AML. This study's patients also tended to have higher-than-average WBC counts, as they had banked cells available for study, however, their treatment outcomes were very similar to those of the SWOG-9031 and SWOG-9333 patients without cells available (results not shown).
The occurrence of a sizable number of deaths caused by toxicity of treatment is an important limitation for the success of therapy for AML. In our study population, we observed a slightly higher rate of toxic deaths (25%) than typically expected among patients with similar characteristics. However, we observed no significant associations between GST genotypes and toxicity in any organ group, although there was a suggestive trend for increased cardiotoxic events among patients with the low activity GSTA1 n B alleles. The anthracyclines cause free radical damage and lipid peroxidation; these events occur readily in cardiac tissue and are mainly responsible for the cardiotoxicity observed with these agents. 1 Thus, it is not unreasonable that there would be an increase in observed cardiotoxicity in those patients with low activity alleles. Larger studies are needed to further address the issue of toxicities.
Because of the complex roles of numerous enzymes involved in drug metabolism and resistance, protection from oxidative stress and DNA repair systems, it is possible that slight effects of a small number of genes may not be detectable without consideration of variability in multiple genes in a number of pathways. Furthermore, the extremely poor prognosis of AML in older patients may also overwhelm subtle effects of genetic variants. Nonetheless, identification of genetic variants that could impact disease-free survival in AML remains an important goal in a pharmacogenetic approach to cancer therapeutics.
